Acadia sells Rare Pediatric Disease Priority Review Voucher for $150M

hapabapa Acadia Pharmaceuticals ( NASDAQ: ACAD ) has sold a Rare Pediatric Disease Priority Review Voucher for $150M. The company received the voucher in March 2023 after the FDA approved Daybue (trofinetide), a Rett syndrome treatment. Acadia said sale proceeds will go to benefit its commercial operations, R&D programs in central nervous system and rare disease, and future business development.

More on Acadia Pharma Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again Acadia Pharmaceuticals appoints Catherine Owen as CEO Seeking Alpha’s Quant Rating on Acadia Pharma Historical earnings data for Acadia Pharma Financial information for Acadia Pharma.